Does Bravecto have any breed specific contraindications?
There are no breed specific contraindications for this product and if this was the case would be included in the contraindications on the Summary of Product Characteristics and datasheet.
Bravecto dosing and a growing puppy
A growing dog should be dosed with a tablet appropriate to the body weight at the time of treatment.
Field studies conducted in support of Bravecto’ marketing authorisation included growing dogs and there was no evidence for a lack of efficacy1,2. Bravecto showed continuous flea efficacy of >99% throughout the 12-week interval in these dogs. The minimum retreatment interval for dogs is 8 weeks3.
1. Meadows et al. Parasites & Vectors 2014, 7:375
2. Rohdich et al. Parasites & Vectors 2014, 7:83
3. Bravecto chewable tablets summary of product characteristics
Can Bravecto be used in epilepsy?
As per the Bravecto Chewable tablet SPC and datasheet, use with caution in dogs with pre-existing epilepsy.
The statement has been included as this represents a very rare trend captured in the Pharmacovigilance data reports over the past 3+ years. This does not demonstrate a causal relationship between Bravecto and seizures. Breakthrough seizures in animals under treatment for epilepsy is fairly normal according to key opinion1. We have no specific safety or efficacy concerns with these dogs and Bravecto has an established safety profile. Bravecto can be used with caution - vet assessment as with any prescription. A dog with epilepsy can experience a seizure due to a wide range of stimuli, and thus caution is always in order.
1. Potschka et al., 2015. International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy. BMC Veterinary Research volume 11, Article number: 177.
Swapping to Bravecto from another flea treatment
There are no known incompatibilities with other classes of ectoparasiticides or parasiticide. It would be a reasonable precaution to observe a normal retreatment interval after the use of another product in the isoxazoline class and in the case of other products to not apply two products simultaneously so it was clear which product use was responsible in the unlikely occurrence of an adverse event.
Bravecto and Environmental impact
MSD Animal Health conducts environmental risk assessments on its products from the development phase through product launch to understand and manage product impacts from manufacturing and patient use. Our environmental risk assessments are conducted in accordance with applicable stringent global regulations, including the regulatory review processes of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Product environmental safety profiles are reassessed during periodic renewals of product filings and risk mitigation actions are implemented when needed.
The potential transfer of active ingredients used in our spot-on and chew products from the dog into surface water has been assessed in the European environmental risk assessments. Based on their intrinsic properties we are confident in the absence of transfer into surface water for the active ingredients in the registered products in our companion animal line. However please be aware of the statement on the EMA Summary of Product Characteristics that dogs treated with Bravecto Spot-On should not be allowed to be immersed in water or swim in water courses within 3 days after treatment. However, there is no specifically identified risk to fish or aquatic species from this activity.
Following oral treatment of dogs fluralaner will mainly be excreted via the faeces, thus exposure of bees to fluralaner is considered very unlikely. Overall, there were no environmental concerns identified in the regulatory submissions or reviews. The environmental exposure through the oral treatment of dogs is considered too low to impact the environment.
What does Bravecto Plus treat?
For cats with, or at risk from, mixed parasitic infestations by ticks or fleas and ear mites, gastrointestinal nematodes or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks or fleas and one or more of the other target parasites is indicated at the same time.
For the treatment of tick and flea infestations in cats providing immediate and persistent flea (Ctenocephalides felis) and tick (Ixodes ricinus) killing activity for 12 weeks. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
For the treatment of infestations with ear mites (Otodectes cynotis).
For the treatment of infections with intestinal roundworm (4th stage larvae, immature adults and adults of Toxocara cati) and hookworm (4th stage larvae, immature adults and adults of Ancylostoma tubaeforme).
When administered repeatedly at a 12-week interval, the product continuously prevents heartworm disease caused by Dirofilaria immitis.
What are the excipients in Bravecto chewable tablets for Dogs?
The excipients in the Bravecto chewable tablets for Dogs are: pork liver flavour, sucrose, maize starch, sodium lauryl sulfate, disodium embonate monohydrate, magnesium stearate, aspartame, glycerol, soya-bean oil and macrogol 3350.
What are the ingredients in Bravecto Spot on solution for Dogs and Cats?
The excipients in the Bravecto Spot on solution for Dogs and Cats are dimethylacetamide, glycofurol, diethyltoluamide, acetone.
What are the ingredients in Bravecto Plus Spot on solution for Cats?
The excipients in the Bravecto Plus Spot on solution for Cats are butylhydroxytoluene, dimethylacetamide, glycofurol, diethyltoluamide (DEET), acetone.
What is the last day that Bravecto can be given?
The shelf-life relates to the period of time the product can be stored until it given to an animal. Thus, if stored correctly, Bravecto can be applied on the last day before expiry and will have the duration of efficacy as per the datasheet.
Further information is available from the SPC, Datasheet or package leaflet.
Not answered your question?
Bravecto® Spot-on for Cats and Bravecto® Chewable Tablets and Spot-on for Dogs contain fluralaner. POM-V.
Bravecto® Plus Spot-on for Cats contains fluralaner and moxidectin. POM-V.
MSD Animal Health UK Limited. Registered office Walton Manor, Walton, Milton Keynes MK7 7AJ, UK. Registered in England & Wales no. 946942.
Advice should be sought from the medicine prescriber.
Use medicines responsibly.
† Bravecto is the only product to provide 12 weeks* flea and tick protection from a single spot-on and chew.
* Bravecto Chew provides 12-week immediate and persistent killing activity against fleas (Ctenocephalides felis), 12-week immediate and persistent killing activity against the ticks Ixodes ricinus, Dermacentor reticulatus and D. variabilis, and 8-week immediate and persistent killing activity against Rhipicephalus sanguineus.
Bravecto Spot-on for dogs provides 12-week immediate and persistent killing activity against fleas (Ctenocephalides felis and Ctenocephalides canis) and 12-week immediate and persistent killing activity against ticks (Ixodes ricinus, Dermacentor reticulatus and Rhipicephalus sanguineus).